Astellas Pharma China, Inc. clinical trials

A country office of Astellas Pharma Inc

The registry lists 24 studies whose lead sponsor is Astellas Pharma China, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 2, 2026.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Astellas Pharma Inc studies →

• A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor TherapyCompletedNCT04995419Phase 2

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation RecipientsCompletedNCT05153915Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation RecipientsCompletedNCT05152628Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through MenopauseCompletedNCT04234204Phase 3

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With MenopauseCompletedNCT04451226Phase 3

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive AspergillosisTerminatedNCT02646774Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNCT04086758Phase 1

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or CandidemiaTerminatedNCT01982071Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive BladderCompletedNCT04562090Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese ParticipantsCompletedNCT04501640Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant RecipientsCompletedNCT02706678Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus SppTerminatedNCT02646800Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus CapsuleTerminatedNCT02268201Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus NephritisCompletedNCT02457221Phase 3

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant RecipientsCompletedNCT03644485Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female SubjectsCompletedNCT04793204Phase 1

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant RecipientsCompletedNCT02392312

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)CompletedNCT03660059Phase 3

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedNCT04143477Phase 1

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal InfectionsCompletedNCT02678598

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency PatientsCompletedNCT01872039Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Preventive Treatment of Tacrolimus Ointment in Children With Atopic DermatitisCompletedNCT01745159Phase 4

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy SubjectsCompletedNCT02138773Phase 1

  Sponsor listed in the registry: Astellas Pharma China, Inc.

• Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese VolunteersCompletedNCT01720212Phase 1

  Sponsor listed in the registry: Astellas Pharma China, Inc.